Soley Therapeutics closed a $200 million Series C to move its stress‑sensing drug candidates into late‑stage development, with a focus on oncology, neurodegeneration and metabolic disease. Investors included existing backers such as the Doug Leone Family Fund and Breyer Capital. The company said a substantial portion of new capital will support its lead acute myeloid leukemia candidate, SOL‑001, toward an IND filing and clinical start in 2026. Soley’s platform targets cellular stress sensing pathways rather than single genetic drivers, a strategy the company argues can uncover upstream therapeutic opportunities across complex diseases. The financing positions Soley to scale IND‑enabling studies and broaden its discovery platform into additional indications.